The Epidemiology of Myelodysplastic Syndromes
The Epidemiology of Myelodysplastic Syndromes
复制标题
DOI：
10.1016/j.hoc.2010.02.011
复制
发表时间：
2010-04-01
影响因子：
2.4
通讯作者：
Sekeres, Mikkael A.
中科院分区：
文献类型：
--
作者：
Sekeres, Mikkael A.
据报道，美国骨髓增生异常综合征（MDS）的发病率为每10万人3.4例，每年新诊断超过10，000例。随着我们的数据采集技术的改进，这一数字被认为是低估了，可能转化为大约60，000人或更多人患有这种疾病。患者在诊断时处于70或80岁，通常表现为血细胞减少症，并有大量输血需求。发生MDS的最常见风险因素包括高龄、男性、既往暴露于化疗或放射治疗、吸烟或在极少数情况下暴露于工业化学品。
The incidence of the myelodysplastic syndromes (MDS) in the United States is reported as 3.4 per 100,000 people, translating to over 10,000 new diagnoses annually. This figure is considered to be an underestimate as our data capture techniques improve, and probably translates to a prevalence of approximately 60,000 people or more living with the disease. Patients are in their seventh or eighth decades at diagnosis, typically present with cytopenias, and have substantive transfusion requirements. The most common risk factors for developing MDS include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to industrial chemicals.